Abstract
The topic of this review covers a very important branch of cancer research, cancer vaccination. The growing knowledge in tumor immunology has evolved rapidly, starting from unspecific generic stimulation of the immune system to more specific approaches based on the availability of tumor antigens. The review covers molecular and cell biology, and pharmaceutical technology of cancer vaccines. Particularly, it is aimed at highlighting the results of cancer vaccines from phase II and III clinical trials, an issue that is of relevance to better understand how cancer vaccines can successfully complement antitumor therapy, including conventional chemotherapy and the recently developed target-based drugs.
Keywords: Cancer, therapeutic vaccines, immunotherapy, clinical trials, investigational drugs, tumor-associated antigen, morbidity, mortality, surgery, chemotherapy, radiation therapy, immune system, exogenous agent, phagocytic cells, neutrophils, monocytes, inflammatory mediators, eosinophils, tumor cells, PROPHYLACTIC, dendritic cell (DC), Food Drug Administration (FDA), hepatitis B virus (HBV), Hepatocellular carcinoma (HCC), papillomaviruses, anus, penis, oropharynx, lipid, carbohydrate, infectious disease, autoimmune disease, Alzheimer's, Xenoantigens, DNA, mammalian cells, oligodeoxinucleotide, Bacteria, monocytogenes, Salmonella typhimurium, Shigella, Mycobacterium, CANCER VACCINES, growth factors, interleukins, anti-tumor, pharmacological, saponin, phospholipid, lymph node, gels, polymer microspheres, endotoxin, pandemic vaccines, memory cells, surface active agents, aluminium hydroxide, Freund's complete adjuvant (FCA), Granulocyte, emulsion, Belagenpumatucel-L, lung cancer, adenocarcinoma, heterogeneity of enrolled patients, glioma, liposomal vaccine, mucin-1, placebo, Breast Cancer, Prostate Cancer, Protein, Pharmexa, pancreatic cancer, Vitespen, Melanoma, constipation, dyspnoea, arthralgia, metastatic colorectal cancer, orphan drug, antigen, pyrexia, symptomatic metastatic, long-term memory immune responses, hormone-refractory prostate, Brain, Temozolomide, vulvar disease, pelvic discomfort, dysplasias, Hodgkin's Lymphoma, lymphotoxic molecules, hyperstimulation
Current Cancer Drug Targets
Title: Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Volume: 11 Issue: 1
Author(s): S. Cecco, E. Muraro, E. Giacomin, D. Martorelli, R. Lazzarini, P. Baldo and R. Dolcetti
Affiliation:
Keywords: Cancer, therapeutic vaccines, immunotherapy, clinical trials, investigational drugs, tumor-associated antigen, morbidity, mortality, surgery, chemotherapy, radiation therapy, immune system, exogenous agent, phagocytic cells, neutrophils, monocytes, inflammatory mediators, eosinophils, tumor cells, PROPHYLACTIC, dendritic cell (DC), Food Drug Administration (FDA), hepatitis B virus (HBV), Hepatocellular carcinoma (HCC), papillomaviruses, anus, penis, oropharynx, lipid, carbohydrate, infectious disease, autoimmune disease, Alzheimer's, Xenoantigens, DNA, mammalian cells, oligodeoxinucleotide, Bacteria, monocytogenes, Salmonella typhimurium, Shigella, Mycobacterium, CANCER VACCINES, growth factors, interleukins, anti-tumor, pharmacological, saponin, phospholipid, lymph node, gels, polymer microspheres, endotoxin, pandemic vaccines, memory cells, surface active agents, aluminium hydroxide, Freund's complete adjuvant (FCA), Granulocyte, emulsion, Belagenpumatucel-L, lung cancer, adenocarcinoma, heterogeneity of enrolled patients, glioma, liposomal vaccine, mucin-1, placebo, Breast Cancer, Prostate Cancer, Protein, Pharmexa, pancreatic cancer, Vitespen, Melanoma, constipation, dyspnoea, arthralgia, metastatic colorectal cancer, orphan drug, antigen, pyrexia, symptomatic metastatic, long-term memory immune responses, hormone-refractory prostate, Brain, Temozolomide, vulvar disease, pelvic discomfort, dysplasias, Hodgkin's Lymphoma, lymphotoxic molecules, hyperstimulation
Abstract: The topic of this review covers a very important branch of cancer research, cancer vaccination. The growing knowledge in tumor immunology has evolved rapidly, starting from unspecific generic stimulation of the immune system to more specific approaches based on the availability of tumor antigens. The review covers molecular and cell biology, and pharmaceutical technology of cancer vaccines. Particularly, it is aimed at highlighting the results of cancer vaccines from phase II and III clinical trials, an issue that is of relevance to better understand how cancer vaccines can successfully complement antitumor therapy, including conventional chemotherapy and the recently developed target-based drugs.
Export Options
About this article
Cite this article as:
Cecco S., Muraro E., Giacomin E., Martorelli D., Lazzarini R., Baldo P. and Dolcetti R., Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives, Current Cancer Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/156800911793743664
DOI https://dx.doi.org/10.2174/156800911793743664 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Diagnostic and Therapeutic Applications of Exosome Nanovesicles in Lung Cancer: State-of-The-Art
Anti-Cancer Agents in Medicinal Chemistry Altered Hyaluronan Biosynthesis and Cancer Progression: an Immunological Perspective
Mini-Reviews in Medicinal Chemistry Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Flavonoid Kaempferol Inhibits the Proliferation and Survival of Human Leukemia HL60 Cells
Current Drug Therapy Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy
Central Nervous System Agents in Medicinal Chemistry TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design The Possibility of Novel Antiplatelet Peptides: The Physiological Effects of Low Molecular Weight HSPs on Platelets
Current Pharmaceutical Design Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Microdialysis: A Technique for Pharmacokinetic-Pharmacodynamic Studies of Oncological Drugs
Current Pharmaceutical Biotechnology Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Tumor-related Molecular Regulatory Mechanisms of Long Non-coding RNA RMST: Recent Evidence
Mini-Reviews in Medicinal Chemistry Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets